BR9901491A - 7-hetero-biciclo [2.2.1] - heptanos. - Google Patents

7-hetero-biciclo [2.2.1] - heptanos.

Info

Publication number
BR9901491A
BR9901491A BR9901491-2A BR9901491A BR9901491A BR 9901491 A BR9901491 A BR 9901491A BR 9901491 A BR9901491 A BR 9901491A BR 9901491 A BR9901491 A BR 9901491A
Authority
BR
Brazil
Prior art keywords
compounds
hetero
heptanes
bicycles
heptanos
Prior art date
Application number
BR9901491-2A
Other languages
English (en)
Inventor
Daniel Yohannes
Mark Werner Bundesmann
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR9901491A publication Critical patent/BR9901491A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

<B>''7-HETERO-BICICLO [2.2.1]-HEPTANOS''<D> São reivindicados compostos da fórmula e seus sais farmaceuticamente aceitáveis, em que R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são definidos como na descrição, intermediários na síntese de tais compostos, composições farmacêuticas contendo tais compostos e métodos de utilização de tais compostos no tratamento de dedordens neurológicas e psicológicas.
BR9901491-2A 1998-04-27 1999-04-26 7-hetero-biciclo [2.2.1] - heptanos. BR9901491A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8310898P 1998-04-27 1998-04-27

Publications (1)

Publication Number Publication Date
BR9901491A true BR9901491A (pt) 2000-05-02

Family

ID=22176228

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9901491-2A BR9901491A (pt) 1998-04-27 1999-04-26 7-hetero-biciclo [2.2.1] - heptanos.

Country Status (5)

Country Link
US (3) US20020035262A1 (pt)
EP (1) EP0955301A3 (pt)
JP (2) JPH11322751A (pt)
BR (1) BR9901491A (pt)
CA (1) CA2269994C (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289574C (en) 1997-05-30 2007-04-24 Neurosearch A/S 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
US6605610B1 (en) * 1997-12-31 2003-08-12 Pfizer Inc Aryl fused azapolycyclic compounds
PT1044189E (pt) 1997-12-31 2008-04-22 Pfizer Prod Inc Compostos azapolicíclicos condensados com arilo
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
PL198156B1 (pl) * 1999-11-12 2008-05-30 Biogen Idec Ma Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6579878B1 (en) * 2000-07-07 2003-06-17 Targacept, Inc. Pharmaceutical compositions and methods for use
US6538010B1 (en) * 2000-11-08 2003-03-25 Research Triangle Institute Compounds and methods for promoting smoking cessation
WO2003018585A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
PL370549A1 (en) * 2001-10-31 2005-05-30 Pfizer Products Inc. Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
DE60228478D1 (de) 2001-11-30 2008-10-02 Pfizer Prod Inc Aryl-annellierte azapolyzyklische verbindungen
BRPI0407714A (pt) * 2003-02-21 2006-02-14 Pharmacia & Up John Company Ll "exo-2r (+)-2-amino-7-azabiciclo[2.2.1]heptano-7-carboxilato de t-butila, intermediário, e processo para os preparar e isolar
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
US8389561B2 (en) 2008-04-30 2013-03-05 Universiteit Gent Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
CA2638573C (en) 2008-04-30 2013-03-12 Universiteit Gent Substituted 7-azabicyclo[2.2.1]heptyl derivatives useful for making pharmaceutical compositions
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
BRPI0921333A2 (pt) 2008-11-28 2015-12-29 Addex Pharmaceuticals Sa derivados de indol e benzoxazina como moduladores de receptores de glutamato metabotrópicos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
US8809365B2 (en) 2009-11-04 2014-08-19 Universiteit Gent 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders
EP2606052B1 (en) 2010-08-20 2016-06-01 Research Triangle Institute Nicotinic receptor compounds
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN102633804B (zh) * 2012-04-19 2014-09-24 中南大学 一种制备7-氮杂双环[2.2.1]庚烷的方法
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314899A (en) * 1992-03-03 1994-05-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Epibatidine and derivatives, compositions and methods of treating pain
US5817679A (en) * 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
WO1994022868A1 (en) * 1993-04-01 1994-10-13 University Of Virginia 7-azabicyclo-[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
JP3637973B2 (ja) * 1993-06-17 2005-04-13 エーザイ株式会社 アザビシクロヘプタン誘導体
AU7474794A (en) * 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
AU701227B2 (en) * 1993-09-10 1999-01-21 Cytomed, Inc Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
FR2713641B1 (fr) * 1993-12-09 1997-04-11 Egyt Gyogyszervegyeszeti Gyar Dérivés de l'épi-épibatidine.
EP0664293A1 (en) * 1993-12-24 1995-07-26 Duphar International Research B.V 2-Phenyl-7-azabicycloheptanes and 6-phenyl-8-azabicyclo
JP2001521523A (ja) * 1997-04-11 2001-11-06 アボツト・ラボラトリーズ 化学的シナプス伝達の制御において有用なフロピリジン、チエノピリジン、ピロロピリジンおよび関連するピリミジン、ピリダジンおよびトリアジン化合物

Also Published As

Publication number Publication date
EP0955301A2 (en) 1999-11-10
US20030236405A1 (en) 2003-12-25
JPH11322751A (ja) 1999-11-24
US20020038028A1 (en) 2002-03-28
EP0955301A3 (en) 2001-04-18
CA2269994C (en) 2003-03-18
CA2269994A1 (en) 1999-10-27
JP2002114679A (ja) 2002-04-16
US20020035262A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
BR9814592A (pt) &#34;compostos azopolicìclicos condensados com arila&#34;
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
BR9713552A (pt) Derivados de pirimidina bicìclicos condensados
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
DE69427704D1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n-disubstituierte-amino-3,4-dihydro-2h-1-benzopyrane
BG103945A (bg) Производни на 4&#34;-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
BG103947A (en) Derivatives of 9-oxymerythromycin
BR9916585A (pt) Moduladores de ccr5
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
BR0113980A (pt) Compostos de succinimida heterocìclicos fundidos e seus análogos, moduladores de função de receptor de hormÈnio nuclear
BR9916680A (pt) Derivados da 3,3-biarilpiperidina e2,2-biarilmorfolina
SE9802208D0 (sv) Novel compounds
DE69229339D1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
BR9910058A (pt) Compostos azapolicìclicos aril-condensados
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
AP9801377A0 (en) Tricyclic erythromycin derivatives.
SE9802209D0 (sv) Novel compounds
SE9504662D0 (sv) New compounds
BR0000901A (pt) Derivados 4-fenil-4-heteroarilpiperidina
BRPI0412880A (pt) compostos azapolicìclicos fundidos a arila
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
ATE286728T1 (de) Verwendung von homocysteinderivaten zur behandlung von bakteriellen infektionen
BR0014052A (pt) Derivados de aminas
BG105549A (en) Use of n-substituted azabicycloalkane derivatives for treating diseases of the central nervous system

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008.